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Abst rac t
Introduction: Chronic obstructive pulmonary disease (COPD) and asthma are the most common chronic respiratory 
diseases worldwide. At the moment, there is no information about the preferences of Polish specialists as regards 
the treatment of asthma and COPD or factors influencing the choice of particular treatment regimens.
Aim: To determine the treatment options most commonly used by experienced pulmonologists and allergists for 
asthma and COPD and to identify the factors affecting the choice of a particular therapy.
Material and methods: The survey included 224 doctors (pulmonologists and allergists) across Poland and con-
cerned patients diagnosed with asthma (n = 4358) and COPD (n = 3062).
Results: In the case of asthma, the most common therapy applied was inhaled glucocorticosteroids and long-acting 
β
2 agonists. According to 27.2% of doctors, combination therapy was used in 70–80% of patients while 23.7% 
declared that the proportion of patients receiving such a treatment exceeded 80%. In the case of COPD, anticholin-
ergics were most frequently prescribed when inhaled glucocorticosteroids and long-acting β
2 agonists had proved 
insufficient. According to 21% of specialists, the percentage of patients treated so was 41–50%, while 19% declared 
the use of this treatment in 71–80% of patients.
Conclusions: The most common treatments for asthma and COPD in Poland are inhaled glucocorticosteroids and 
long-acting β
2 agonists. The main factors influencing treatment decisions are the current GINA and GOLD recom-
mendations as well as patients’ age, comorbidities, and price of treatment. 
Key words: asthma, chronic obstructive pulmonary disease, therapeutic preferences, therapeutic regimens.
Introduction
Chronic obstructive pulmonary disease (COPD) and 
asthma are the most common chronic respiratory dis-
eases worldwide [1–3]. 
Chronic obstructive pulmonary disease represents 
a serious public healthcare challenge and is one of the 
major causes of chronic morbidity and mortality through-
out the world and is predicted to be the third leading 
cause of death by 2020 [1, 3]. According to the 2017 GOLD 
report, COPD is a preventable and treatable disease 
which is characterized by persistent respiratory symp-
toms (dyspnoea and sputum production) and airflow 
obstruction due to airway and/or alveolar abnormali-
ties usually caused by significant exposure to noxious 
particles or gases [1]. Tobacco smoking is considered the 
most important COPD risk factor but other environmen-
tal exposures such as biomass fuel exposure and air pol-
lution may also contribute. It is estimated that in Poland 
around two million people suffer from COPD. Airflow 
obstruction GOLD ≥ 2 (moderate degree of obstruction) 
may be found in approx. 10% of the Polish population 
over the age of 40. 
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Chronic obstructive pulmonary disease assessment 
must include the severity of airflow obstruction (spiro-
metrically measured), proper symptoms’ evaluation 
(assessed objectively with appropriate questionnaires), 
obtaining the history and future risk of exacerbation and 
presence of comorbidities [2, 3]. The latest GOLD guide-
lines propose a new approach to COPD assessment by 
separating spirometric grades from the “ABCD” groups 
[3]. Spirometry still remains the first-line tool to confirm 
irreversible airflow obstruction but respiratory symptoms 
and exacerbation history are crucial for therapeutic ap-
proaches. 
The goal of the COPD therapy is to reduce symptoms 
as well as the frequency and severity of exacerbations, 
and improve exercise tolerance and overall health sta-
tus. The classes of medications commonly used to treat 
COPD include bronchodilators that increase forced expi-
ratory volume in 1 s (FEV
1
) and/or change other spiromet-
ric variables. They are most often prescribed on a regular 
basis to prevent or reduce symptoms. The first group of 
bronchodilators consists of β
2
-agonists both short-acting 
(SABA) and long-acting (LABA) ones. Formoterol and sal-
meterol are twice-daily LABAs. Indacaterol, olodaterol and 
vilanterol are additional once-daily LABAs. The second 
important group of bronchodilators comprises antimus-
carinic drugs: short-acting antimuscarinics (SAMAs) such 
as ipratropium and long-acting antimuscarinic antago-
nists (LAMAs) including tiotropium, aclidinium, glycopyr-
ronium bromide and umeclidinium. Anti-inflammatory 
drugs are represented by inhaled glucocorticosteroids 
(ICS), oral glucocorticosteroids (OCS), phosphodiester-
ase-4 (PDE4) inhibitors (roflumilast), mucolytics and an-
tibiotics. These are mentioned only when used in com-
bination with bronchodilators. The latest GOLD report 
also points out to the significance of non-pharmacologic 
strategies including smoking cessation, education, self-
management and pulmonary rehabilitation. Stable COPD 
pharmacologic treatment regimen proposed by GOLD 
2017 guidelines has been summarized in Table 1. 
Asthma is a heterogeneous, chronic obstructive in-
flammatory airway disease affecting up to 18% of popu-
lation in different countries. The prevalence of asthma 
in Poland is estimated at 5% of the population. It is 
characterized by symptoms of airflow limitation such as 
wheeze, shortness of breath or cough which, in contrast 
to COPD, may vary over time. Asthma may be manifest-
ed in various clinical phenotypes that require different 
clinical approach and management. Diagnosis of asthma 
is based on the presence of typical symptoms and the 
evaluation of variable airflow limitation measured mainly 
by the lung function test and peak expiratory flow rate 
evaluation. In certain phenotypes of asthma, other clini-
cal tools such as allergy and bronchial provocation tests 
are useful for diagnosis. Once the diagnosis is estab-
lished, the level of asthma control should be assessed. It 
includes the evaluation of certain symptoms’ frequency: 
daytime symptoms, nocturnal awakenings due to asth-
ma, need for relief medication and limitation of physical 
activity. On the basis of these criteria and in accordance 
with the current GINA guidelines, asthma is classified as 
controlled, partly controlled, and uncontrolled.
The treatment regimen depends not only on the level 
of asthma control but it is also shaped by severity of air-
flow limitation, risk of exacerbation, presence of comor-
bidities, patient preferences and ability to use different 
types of inhalers. The goal of the therapy is to achieve 
the best available control of the symptoms, to improve 
the quality of life and to minimize the risk of disease ex-
acerbation. The current (2107) GINA guidelines propose 
a control-based asthma management protocol and point 
out to other asthma treatment strategies that may play 
an important role in severe or difficult to treat asthma 
e.g. sputum-guided treatment or fractional concentration 
of exhaled nitric dioxide (FeNO)-guided regimen. Inhala-
tion therapy is the principal therapeutic modality in all 
asthma phenotypes. Asthma medications can be divided 
into three main groups: 
• Controller medications – reduce airway inflammation, 
patient symptoms and risk of asthma exacerbation. 
These include ICS (beclomethasone, budesonide, cicle-
sonide, fluticasone and mometasone), antileukotriene 
drugs (montelukast, zafirlukast), LABA (formoterol, sal-
meterol), tiotropium and theophylline. 
• Relievers – include SABA (fenoterol, salbutamol) and com-
bination of low-dose ICS and formoterol in one inhaler. 
• Add-on therapies which should be considered in the 
cases of all patients with poor response to treatment 
(e.g. tiotropium and omalizumab). 
Table 1. GOLD 2017 recommendations for stable chronic 
obstructive pulmonary disease treatment
C
LAMA
or
LAMA + LABA
or
LABA + ICS
(if further exacerbations 
occur)
D
LAMA + LABA
or 
LAMA + LABA + ICS
(if further exacerbations occur) 
or 
LAMA
or
LABA + ICS 
+ roflumilast (FEV11 < 50%  
and chronic bronchitis)
A
Bronchodilator
(if symptoms persist, 
an alternative class of 
bronchodilator)
B
LABA
or
LAMA
or
LABA + LAMA
(if symptoms persist) 
LABA – long-acting β
2
-agonists, LAMA – e.g. long-acting anticholinergics, ICS 
– inhaled glucocorticosteroids.
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The 2017 GINA guidelines recommend a stepwise 
pharmacologic treatment regimen for asthma which are 
summarized in Table 2. The document also indicates im-
portance of non-pharmacologic interventions in asthma. 
These mainly include guided self-management education 
and several strategies e.g. weight loss, increased physical 
activity, and avoidance of sensitizers and proper manage-
ment of comorbidities. 
Aim
The aim of this study was to determine the asthma 
and COPD treatment regimens most commonly used by 
experienced pulmonologists and allergists and to identify 
the factors affecting the choice of a particular therapy. 
The data obtained in this paper may help to identify the 
patterns applied in the therapeutic decision-making pro-
cess as well as patient adherence issues.
Material and methods
The survey was conducted across Poland in the first 
half of 2016 and was concerned with patients diagnosed 
with asthma and COPD. The doctors received a question-
naire which they completed and returned to the research 
centre. The questionnaire consisted of two parts. Part 
A contained questions concerning statistical data referring 
to the doctors: how long the doctor worked in the profes-
sion, place of work (city/village and public/private hospital 
or public/private clinic), the number of patients seen per 
month, the percentage of patients diagnosed with asthma 
and COPD in a month, and the percentage of patients who 
used the listed groups of drugs (alone or in combination). 
Part B consisted of questions concerning patient charac-
teristics including demographics, education and occupa-
tion, place of residence (urban/rural), initial diagnosis at 
baseline, disease duration, the degree of disease control, 
the number of exacerbations, and hospitalizations in the 
past 3 months and prescribed treatment regimens. 
Based on the questionnaires we conducted an analy-
sis of the doctors’ (allergists and pulmonologists spe-
cializing in the treatment of asthma and COPD) and pa-
tients’ preferences depending on the doctors’ length of 
service, patients’ age and professional activity, treatment 
duration and occurrence of comorbidities.
Results
A total of 224 doctors responded to the question-
naire. Out of these, 78% were pulmonologists, 21% aller-
gists; 69% had over 20 years of professional experience. 
The doctors were mainly employed by different clinics: 
54.9% – public and 15.6% – private, while hospital was 
the principal place of work for 21.9% of doctors. The 
majority of doctors (90.6%) worked in cities. Each saw 
an average of 400 patients per month. The number of 
patients they saw with asthma or COPD in most cases 
ranged from 20 to 50 per month.
The survey was conducted on a group of 7420 pa-
tients (4009 males; 54%) out of whom 4358 had been 
diagnosed with asthma and the remaining 3062 with 
COPD. The average patient age was 50.6 ±16.9 years. 
Of the respondents, 23.5% were rural residents, 61.4% 
of patients were still working. In a majority of respon-
dents, the illness had lasted for over 5 years. During the 
3 months prior to the survey, 27.43% of patients with 
asthma and 48% patients with COPD experienced at 
least one exacerbation. In the 3 months prior to the 
study, 4.4% of patients with asthma required hospitaliza-
tion due to exacerbation. In patients with COPD, the hos-
pitalization percentage was 23.3%. Asthma was rated as 
controlled in 55% of patients. Out of the total of patients 
with COPD, 65.9% were classified as GOLD category C 
and D. Detailed medical records are included in Table 3.
Table 2. Asthma pharmacological treatment stepwise approach according to GINA 2017
Intensity levels of asthma 
treatment
Preferred controller choice Other controller option Reliever 
Step 1 Low-dose ICS Consider low-dose ICS As-needed SABA
Step 2 LTRA
Low-dose theophylline 
Step 3 Low-dose ICS/LABA Medium/high-dose
ICS/LABA 
Low-dose ICS + LTRA
(or + theophylline)
As-needed SABA or  
low-dose ICS/formoterol
Step 4 Medium/high-dose
ICS/LABA 
Add tiotropium 
High-dose ICS + LTRA 
(or + theophylline)
Step 5 Refer for add-on treatment
(e.g. tiotropium, omalizumab)
Add low-dose OCS
ICS – inhaled glucocorticosteroids, SABA – short-acting β
2
-agonists (e.g. fenoterol and salbutamol), LABA – long-acting β
2
-agonists (e.g. formoterol and salme-
terol), OCS – oral glucocorticosteroids.
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The majority of doctors surveyed declared that their 
most common (49.5%) therapeutic decision in patients 
with asthma was the prescription of ICS and LABA, and 
27.2% declared that they prescribed combination therapy 
in 70–80% of patients. According to 23.7% of doctors, 
the percentage of patients receiving such treatment ex-
ceeded 80%. Other frequently used treatment options 
were also short-acting β
2
 mimetics and ICS. Theophylline 
was rarely used in these patients. The key factors to influ-
ence the therapeutic decisions were the GINA guidelines 
(66.5% of respondents). Other factors strongly affecting 
treatment decisions were etiological ones associated 
with the development of the disease, comorbidities, the 
price of the drug and patient preference. 
A detailed overview of therapeutic decisions in pa-
tients with diagnosed asthma is presented in Table 4.
For patients with COPD, the most common thera-
peutic approach has been the inclusion of an anticho-
linergic drug, followed, as in the case of asthma, by ICS 
and LABA. The doctors also often declared prescribing 
SABA. According to 21% of doctors, the percentage of pa-
tients receiving combination therapy with ICS and LABA 
ranged from 41% to 50%. The above scheme was applied 
by 19% of specialists in 71–80% of patients and only 6.3% 
declared using it in more than 80% of patients. The key 
factor influencing treatment decisions were the GOLD 
recommendations (65% of respondents). Quality of life, 
morbidity, and co-occurrence of asthma also played an 
important role in the treatment selection process. A de-
tailed presentation of therapeutic decisions in patients 
diagnosed with COPD is featured in Table 5.
In their treatment of patients with asthma, both pul-
monologists and allergists were willing to prescribe com-
bination treatment with ICS and LABA. Allergists were 
much more likely to select SABA. As far as other groups 
of drugs were concerned, the specialists acted quite 
similarly taking their decisions mostly in accordance with 
the GINA guidelines, the etiologic factors of the disease, 
quality of life, and concomitant diseases. Allergists, more 
often than pulmonologists, took account of other factors 
such as the price of the drug and patients’ preferences. 
The differences in treatment preferences were less no-
ticeable in patients with COPD. Allergists often declared 
the use of combined treatment with ICS and LABA in 
this group of patients and prescribed drugs from other 
groups with similar frequency as the pulmonologists. 
There were no significant differences between the spe-
cialists in terms of the factors influencing the choice of 
a particular therapeutic regimen. A detailed overview of 
therapeutic decisions in patients with diagnosed asthma 
and COPD are presented in Tables 4 and 5.
The doctors’ length of service did not significantly in-
fluence their therapeutic decisions in patients with asth-
ma as these were usually based on the GINA guidelines. 
In patients with COPD, specialists with a shorter length 
of service often opted for a particular therapy taking into 
account patient age and asthma comorbidity. For doctors 
with longer professional experience, more important fac-
tors were the price, tolerability of the drug, and patients’ 
personal preferences. The GOLD guidelines however were 
the most important factor for all the surveyed doctors 
during their therapeutic decision-making process.
Table 3. Data from patient interview
Parameter Asthma (n = 4358) COPD (n = 3062)
Duration of the disease, n (%):
 < 3 months 113 (2.6) 26 (0.8)
 3–6 months 104 (2.4) 25 (0.8)
 7–12 months 170 (3.9) 67 (2.2)
 1–2 years 326 (7.5) 148 (4.8)
 2–3 years 763 (17.5) 594 (19.4)
 4–5 years 823 (18.9) 626 (20.4)
 > 5 years 2059 (47.2) 1576 (51.5)
Exacerbation of the disease in the last 3 months, n (%) 1196 (27.4) 1470 (48.0)
If so, how many? Mean ± SD 1.3 ±0.6 1.4 ±0.6
Hospitalization due to worsening in the last 3 months, n (%) 193 (4.4) 714 (23.3)
If so, how many? Mean ± SD 1.1 ±0.3 1.1 ±0.3
Severity, n (%):
 Asthma controlled/Category A 2395 (55.0) 261 (8.5)
 Asthma partly controlled/Category B 1661 (38.1) 782 (25.5)
 Asthma uncontrolled/Category C 302 (6.9) 1231 (40.2)
 Category D 788 (25.7)
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Regardless of their workplace, the doctors in the sur-
vey prescribed combination therapy with ICS and LABA 
in patients with asthma. Compared with hospital treat-
ment, outpatient clinics more often used inhaled GCS, 
short-acting β
2
-adrenergic agonists and antileukotrienes. 
The doctors working at hospitals more often took into 
account their patients’ age and etiological factors of the 
disease. In outpatient clinics, emphasis was placed on 
the preferences of the patient and the price of the drug. 
Most often and independently of the location, thera-
peutic decisions were based on the GINA guidelines. In 
the hospital patients with COPD, anticholinergics were 
frequently used. The factors that influenced therapeutic 
decisions in hospitals and outpatient clinics were similar, 
the most important being the GOLD guidelines. In the 
outpatient clinics, patients’ preferences and the price 
of drug were more important just like in the case of the 
patients with asthma. The most commonly used thera-
peutic regimens for asthma and COPD depending on the 
specialist are presented in Table 6.
Analysis was also conducted in reference to the pa-
tient-doctor collaboration in the treatment of asthma 
and COPD. It was estimated that in the case of asthma, 
medical recommendations were applied by 91.0% of men 
and 92.2% of women while in COPD these ratios were 
85.7% and 88.4%, respectively. Significantly lower levels 
of adherence to medical recommendations were found 
in COPD patients, especially younger ones (≥ 40 years). 
Only 68.3% of COPD patients adhered to their doctors’ 
recommendations (vs. 90.9% in the case of asthma). The 
level of education was also another important therapy 
adherence predictor in COPD patients as only 81.5% of 
patients with vocational training complied with the rec-
ommendations of their doctors (vs. 95.2% of COPD pa-
tients with higher education).
Discussion
Patients with obstructive lung diseases are usually 
seeking advice in both pulmonary and allergy clinics. 
In the Polish healthcare system, pharmacotherapy pre-
Table 6. Treatment applied 
Treatment Asthma
(n = 4358)
COPD
(n = 3062)
Treatment applied, n (%):
Short-acting inhaled β
2-mimetic
(sa. i. β2-M)
1300 
(29.8)
1949 (63.6)
 Long-acting inhaled β2-mimetic 
(la. i. β2-M)
3153 
(72.3)
2825 (92.3)
Inhaled glucocorticosteroids (ICS) 4140 
(95.0)
2069 (67.6)
Antileukotriene (aleuc.) 1784 
(40.9)
–
Anticholinergic (ACH) – 2237 (73.1)
Theophylline (T) 400 (9.2) 1014 (33.1)
Oral glucocorticoid (oral GCS) 201 (4.6) 311 (10.2)
Anti-IgE 23 (0.5) –
Inhibitor of phosphodiesterase 4 
(iPD4)
– 57 (1.9)
Combination therapy*:
ICS + la. i.β2-M 748 (17.2) 289 (9.4)
ICS + la. i.β
2-M + aleuc. 230 (5.3) –
ICS + la. i.β
2-M + T 33 (0.8) 28 (0.9)
ICS + la. i.β
2-M + aleuc. + T 30 (0.7) –
ICS + la. i.β
2-M + sa. i.β2-M 922 (21.2) 209 (6.8)
ICS + la. i.β
2-M + sa. i.β2-M + T 75 (1.7) 50 (1.6)
ICS + la. i.β
2-M + sa. i.β2-M + aleuc. 744 (17.1) –
ICS + la. i.β
2-M + sa. i.β2-M + aleuc. 
+ after GCS
53 (1.2) –
ICS + la. i.β2-M + sa. i.β2-M + aleuc. 
+ T
146 (3.5) –
Treatment Asthma
(n = 4358)
COPD
(n = 3062)
ICS + la. i.β2-M + sa. i.β2-M + aleuc. 
+ T + oral GCS
76 (1.7) –
ICS + la. i.β2-M + sa. i.β2-M + oral 
GCS
26 (0.6) –
ICS + sa. i.β2-M 462 (10.6) –
ICS + sa. i.β
2-M + aleuc. 383 (8.8) –
ICS + aleuc. 28 (0.6) –
ICS + la. i.β2-M + ACH – 174 (5.7)
ICS + la. i.β
2-M + ACH + T – 135 (4.4)
ICS + la. i.β
2-M + ACH + oral GCS – 30 (1.0)
ICS + β
2-M kr. (w) + iPD4 – 20 (0.6)
ICS + la. i.β
2-M + sa. i.β2-M + ACH – 443 (14.5)
ICS + la. i.β
2-M + sa. i.β2-M + ACH + 
oral GCS
– 35 (1.1)
ICS + la. i.β2-M + sa. i.β2-M + ACH + T – 449 (14.7)
 ICS + la. i.β
2-M + sa. i.β2-M + ACH + 
T + oral GCS
– 155 (5.1)
ICS + la. i.β2-M + sa. i.β2-M + ACH + 
T + oral GCS + iPD4
– 9 (0.3)
la. i.β2-M + sa. i.β2-M 17 (0.4) 38 (1.2)
sa. i.β
22-M + aleuc 55 (1.3) –
ACH + la. i.β
2-M – 220 (7.2)
ACH + la. i.β2-M + T – 26 (0.8)
ACH + sa. i.β2-M – 61 (2.0)
ACH + la. i.β2-M + sa. i.β2-M – 323 (10.5)
ACH + la. i.β2-M + sa. i.β2-M + T – 88 (2.9)
*Does not include schemes used in less than 9 persons. sa. i. β
2
-M – short-acting inhaled β
2
-mimetic, la. i. β
2
-M – long-acting inhaled β
2
-mimetic, ICS – inhaled 
glucocorticosteroids, aleuc. – antileukotriene, ACH – anti cholinergic, T – theophylline, GCS – oral glucocorticoid, iPD4 – inhibitor of phosphodiesterase 4.
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scribed by specialists in asthma and COPD is a crucial 
factor determining the long-term treatment of these 
patients. This study, conducted with the participation of 
experienced professionals on a large group of patients, 
is an attempt to answer the questions of how the treat-
ment of asthma and COPD is carried out by pulmonolo-
gists and allergists in their everyday clinical practice as 
well as what factors influence the choice of a particular 
therapy.
Pulmonologists and allergists should first pay at-
tention to the population of patients participating in 
the study. Most patients with COPD were classified as 
category C and D and among patients with asthma only 
just over a half were characterized by a good degree of 
control. Most patients had been suffering from asthma 
or COPD for many years. Over 25% of the patients with 
asthma and 50% of those suffering from COPD had ex-
perienced exacerbation of the disease within 3 months 
prior to the study. In many cases they required hospi-
talization. These findings certainly should be taken into 
account when selecting pharmacotherapy.
The preferred therapeutic option for pulmonologists 
and allergists was to prescribe a combination of inhaled 
corticosteroids and long-acting β
2
-adrenergic agonists, 
both to patients with asthma and COPD. Frequent use 
of such a combination therapy for asthma is fully un-
derstood and both agents are in fact the basis of phar-
macotherapy in these diseases, particularly if control is 
insufficient. The benefits of combination therapy have 
been confirmed by the results of the patients included in 
this study. In this context it is not surprising that (more 
frequently than in COPD) ICS with β
2
-adrenergic ago-
nists are recommended by the GINA especially in milder 
forms of asthma as one of the main therapeutic op-
tions. The widespread use of combination therapy with 
inhaled corticosteroids and long-acting β
2
-adrenergic 
agonists may however raise some doubts in the case 
of COPD patients. While bronchodilators are the initial 
recommended treatment, indications for ICS are limited. 
The ICS are prescribed in COPD categories C and D, in 
patients with frequent exacerbations, and are always 
combined with bronchodilators. The widespread ap-
plication of combination therapy consisting of inhaled 
corticosteroids and LABA reported in this study could 
be associated with the group of patients included in 
the study. Most COPD patients were enrolled for C and 
D GOLD categories, nearly half had experienced exacer-
bation of the disease and hospitalization was required 
in every fourth patient. Undoubtedly, the frequent use 
of anticholinergic drugs in COPD patients is a positive 
phenomenon. Research shows that their therapeutic 
efficacy (long-acting anticholinergics) is comparable to 
treatment with an inhaled corticosteroid and long-acting 
β
2
-adrenergic agonists, with a lower risk of adverse reac-
tions (particularly pneumonia) associated with the intake 
of inhaled glucocorticoids. Tiotropium, a long-acting mus-
carinic antagonist, also has an established place in the 
GINA guidelines since it is prescribed for severe asthma 
(4th step of therapy) but in the Polish health care system 
its use in asthma is still insignificant as it is expensive 
and not refunded. Another positive phenomenon is less 
frequent use of theophylline in COPD patients, especially 
in these with asthma. This drug has rather low thera-
peutic effectiveness and involves a considerable risk of 
serious side effects.
Patients’ compliance with recommendations is a sig-
nificant clinical issue which cannot be overlooked in the 
treatment of asthma and COPD and the most important 
factor in obtaining adequate control of the disease and 
prevent exacerbations as well as potential hospitaliza-
tions. 
Reviewing the latest literature in the field of obstruc-
tive lung diseases, adherence to therapy in asthma and 
COPD was a frequent subject of research [4–8]. The re-
sults of the present study confirm that the GINA and 
GOLD guidelines are the essential factors determining 
the specialists’ choice of therapy regimen. Noteworthy 
is the fact that both pulmonologists and allergists take 
into account not only guidelines but also other crucial 
factors that may affect adherence to therapy. In clinical 
practice, the factor that often turns out to be the key 
one for poor adherence is patients’ age [4, 5]. Advanced 
age is frequently associated with cognitive impairment. 
In O’Conor’s study [4], 27% of asthmatic patient popula-
tion (mean age of the sample was 67 years) were classi-
fied as high cognitive impairment according to the mini-
mental status examination score. Authors emphasized 
that decreased cognitive function may be associated not 
only with a poor inhalation technique but may also affect 
other parts of the disease treatment plan i.e. using a dif-
ferent type of medications (maintenance vs. emergency), 
recognizing exacerbations and general healthcare self-
management. Cognitive dysfunction may also play an im-
portant role in comorbidity that strongly affects not only 
adherence to therapy but overall treatment outcomes as 
well. In Turan study [5], mistakes in the inhalation tech-
nique in elderly both asthmatic and COPD patients were 
present in 90% of individuals and were more frequent in 
COPD patients. The results of the present study confirm 
observation of poor adherence in COPD patients, what 
seems to be a serious clinical problem in all chronic respi-
ratory diseases with hypoxemia. Cognitive dysfunction is 
frequently associated with a low socioeconomic status, 
another poor therapy adherence risk factor [4–6]. In the 
present study, the problem of non-compliance with the 
doctor’s instructions was a frequent finding in less edu-
cated COPD and asthmatic patients. The socioeconomic 
status in the Polish healthcare system plays an additional 
important role because of great reimbursement differ-
ences for certain therapy agents. In the present study, the 
agent price proved to be one of the key ones in terms of 
patients’ treatment compliance, being clearly more often 
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recognised by more experienced professionals. In con-
trast to this observation, Voorham et al. [6] did not prove 
that prescription charges impact therapy adherence and 
diseases outcomes. It can be explained by differences in 
the healthcare system and general higher economic sta-
tus in Western Europe countries comparing to Poland. 
The present study also indicates the importance of pa-
tient preferences for a particular product and the type 
of inhaler. This observation is supported by the Dutch 
research [7]. Authors concluded that adherence to inha-
lation therapy for COPD treatment is strongly related to 
the medication prescribed, pointing out tiotropium as 
an agent with the best level of adherence. It can be ex-
plained not only by efficacy of this agent but probably by 
the dosing regimen (once a day) and the inhaler type. 
Referencing this observation to Polish COPD population, 
the high frequency of using combined inhalers may also 
have a purpose of improving compliance. An asthma 
adherence determinant was the subject of a separate 
systematic review [8]. Findings suggest that adults with 
asthma better adhere to therapy if they are well informed 
and better educated about the disease and are less con-
cerned about using inhalers. However, younger adult pa-
tients may be more at risk of nonadherence. This obser-
vation is consistent with the present study. 
Conclusions
The results of this study suggest further that the 
overall degree of Polish patient compliance is high. This 
observation may however raise some doubts, especially 
in the context of the prevalence of exacerbations and 
insufficient disease control, pointing to the need for con-
tinuous education of both patients and physicians.
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